Sodium Formaldehyde Sulphoxylate Veterinary Grade API for Tablets / Injections / Capsules / Powders / Granules / Premix / Solutions is a hydrated sodium hydroxymethanesulfinate supplied as a white to off-white crystalline powder. The anhydrous form carries CAS 149-44-0 and a molecular weight of 118.09 g/mol; the dihydrate is identified as CAS 6035-47-8 with a molecular weight of 154.12 g/mol. Commercial model designations are supplier-specific, while the controlled identity for veterinary use is defined by the CAS registry, the water content of the declared hydrate, and the release specification for residual formaldehyde. In redox-sensitive veterinary formulations, the substance functions as a reducing agent and oxygen scavenger. Because the molecule exists in aqueous equilibrium with formaldehyde and sulfoxylate species, grade selection is managed through limit tests rather than by compendial identity alone.

Aqueous solubility at 25 °C allows direct preparation of 10% w/v stock solutions; after membrane filtration through a 0.45 µm cellulose acetate filter, the solution is typically clear under Ph. Eur. 2.2.1 visual clarity conditions. Ethanol solubility is negligible, and therefore organic solvent granulation is not a primary processing route. The dry powder is hygroscopic above 60% RH; opened containers are re-sealed under nitrogen to limit caking and loss of reducing titer.

At the production scale, batch-to-batch variance in reducing titer is monitored by iodometric titration on three sampling levels per drum. Data from a 50 kg stainless steel ribbon blender show that titer inhomogeneity remains below 0.8% RSD when blending time exceeds 15 min at 12 rpm; shorter blending times produce localized high moisture zones. The powder is discharged through a 1.0 mm mesh to remove soft agglomerates before sampling.

Why is residual formaldehyde a release criterion for veterinary premix and solution applications?

Residual formaldehyde in the API arises from the reversible dissociation of sodium hydroxymethanesulfinate in aqueous systems. In premixes buffered at pH 6.5–7.5, temperature elevation shifts the equilibrium toward free formaldehyde. A release limit of not more than 0.5% w/w on the anhydrous basis is applied, determined by HPLC with 2,4-dinitrophenylhydrazine derivatization and detection at 360 nm. For injectable preparations, the same limit is supplemented by a formulation-level stability challenge in nitrogen-purged sealed ampoules. Published data for species-specific injection matrices is limited, and the release value is therefore treated as a critical quality attribute rather than a predictive toxicological threshold.

Parenteral-grade processing uses a solution prepared at 0.05–0.2% w/v of the API, with osmolality correction required when the addition exceeds 0.2% w/v. Bacterial endotoxins are controlled at NMT 0.5 EU/mg by Ph. Eur. 2.6.14 or USP <85>. Subvisible particulates are assessed against USP <788> Method 1 limits after aseptic filtration through a 0.22 µm polyvinylidene fluoride membrane. Nitrogen sparging before filtration reduces dissolved oxygen below 0.5 mg/L; the solution is protected from light and stored in borosilicate or multilayer plastic vessels because sulfoxylate species are photo-labile in dilute solution.

For injectable solutions, dissolved oxygen at 25 °C is reduced from 6.2 mg/L to 0.4 mg/L by nitrogen sparging through a 0.2 µm sintered stainless steel sparger at 0.5 L/min per litre of solution. The pH after addition of the API rises by 0.3–0.5 units, and phosphate-buffered systems are used to hold the final pH at 6.8–7.2. Terminal filtration is performed through a 0.22 µm polyethersulfone membrane that has been pre-rinsed with 2 L of water for injection to remove extractables.

Loss on drying, residue on ignition, and related reducing impurities in dry API

The dry API is controlled against a release profile that separates hydrate water from organic volatiles. Loss on drying at 105 °C for 2 h is not used as the sole water measure because formaldehyde loss can occur simultaneously; Karl Fischer titration is therefore the primary water method for dihydrate grade. Reducing impurities are quantified by iodometric titration, and residual formaldehyde is measured separately by derivatization.

Residual solvents are controlled under VICH GL18 for veterinary medicinal products; when dried under reduced pressure at 40 °C, the API retains acceptable flow for direct compression only if milled to a particle-size distribution with D90 below 150 µm. Bulk density is typically 0.55–0.75 g/cm³; tapped density is reported with Ph. Eur. 2.2.42. Published data for this specific configuration is limited, so the tap density range is confirmed on the certificate of analysis rather than treated as a compendial limit.

Method transfer between manufacturing sites uses the same iodometric titration and HPLC derivatization procedures; system suitability for the HPLC method requires baseline resolution between formaldehyde-DNPH and reagent peaks with a resolution factor of not less than 2.0. Linearity for residual formaldehyde is established between 0.01% and 1.0% w/w with a correlation coefficient of 0.999 or greater. Recovery at the 0.1% spike level is 95–105%.

When the API is granulated with hygroscopic excipients below 40% relative humidity

High-shear granulation of tablets containing the API is initiated only after the processing room is held below 40% RH and the granulator bowl jacket is maintained at 25 °C. Wet massing time is limited because prolonged exposure to water accelerates dissociation to free formaldehyde and reduces the iodometric titer. A top-drive high-shear granulator with a 10 L bowl and a peripheral chopper speed of 1500 rpm is used for pilot batches; water addition is stopped when the end-point torque reaches 2–3 N·m. Fluid-bed drying is performed with inlet air at 50 °C and a dew point below 4 °C until the granule moisture is 2.0–3.5%. Over-drying below 2.0% increases friability and reduces tablet hardness at a given compression force.

In a fluid-bed dryer with a 5 kg batch capacity, the pressure drop across the product bowl is held at 0.8–1.2 kPa. Inlet air humidity above 8 g/kg dry air extends drying time and increases granule surface moisture; this is corrected by desiccant dehumidification rather than by raising temperature beyond 50 °C, because higher temperatures darken the granule and reduce titer by more than 2% per hour.

Direct compression of capsules and tablets is limited to formulations where the API content is below 25 mg per unit and the final blend loss on drying is below 3.0%. The API is pre-blended with microcrystalline cellulose and croscarmellose sodium before adding magnesium stearate at 0.5% w/w for 3 min. Tablets are compressed on a rotary tablet press equipped with 10 mm round tooling; ejection force above 800 N indicates punch lubrication failure and requires immediate shutdown for die-table cleaning. Capsules are filled on a dosator machine with nitrogen-purged hopper; powder bed humidity is maintained below 35% RH to prevent dose weight drift.

For powders and granules packaged in unit-dose sachets, the fill weight is adjusted to deliver the required reducing titer per sachet; foil laminate material with a moisture vapor transmission rate below 0.5 g/m²·day is used. Long-term stability studies at 25 °C/60% RH and intermediate 30 °C/65% RH conditions are applied, with assay and residual formaldehyde tested at 0, 3, 6, 9, 12, 18, and 24 months. Published data for this specific configuration is limited, so the shelf-life specification is derived from the first three production batches and not from compendial tables.

For drinking-water premixes and solutions, the API is dispersed at 0.1–0.3% w/w in a carrier such as lactose monohydrate or sodium chloride. Water hardness above 250 mg/L CaCO3 can reduce reductive capacity by precipitating sulfate byproducts; chelating agents are not routinely included because transition-metal sequestration can alter the sulfoxylate oxidation pathway. Solutions are prepared no more than 24 h before administration because the reducing titer declines by 8–15% under uncovered storage at 30 °C. Light-protected high-density polyethylene containers with minimal headspace are used to limit oxygen ingress.

Relative to other reducing agents used in veterinary dosage forms, the product differs in pH stability, oxidation products, and sensitivity to transition metals. Sodium metabisulfite is effective in acidic media and releases sulfur dioxide; sodium formaldehyde sulfoxylate remains active in neutral-to-alkaline formulations and releases formaldehyde as a dissociation product, which must be controlled. Ascorbic acid is an acidic oxygen scavenger and can participate in browning reactions with reducing sugars; the sulfoxylate species does not carry the same carbonyl chemistry. Sodium thiosulfate is used for oxidative neutralization but has lower reducing capacity per unit mass in alkaline solution.

Copper and iron ions at concentrations above 1 ppm accelerate sulfoxylate oxidation exothermically; contact with stainless steel processing surfaces is acceptable only when the surface is passivated. The API is not combined with amine-based additives in aqueous solutions because amine-sulfoxylate interaction reduces the available reducing titer and can produce colored condensation products. Terminal steam sterilization of injectable formulations containing the API is avoided at 121 °C because the sulfoxylate-formaldehyde equilibrium shifts and residual formaldehyde increases beyond the release limit; aseptic filtration is the preferred sterilization route.